MEDI-528, an anti-IL-9 humanized antibody for the treatment of asthma

Current Opinion in Molecular Therapeutics

Volumn 12, Issue 2, 2010, Pages 233-239

  Antoniu, Sabina A ^a  

^a GRIGORE T POPA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; CYTOKINE ANTIBODY; IMMUNOGLOBULIN E; INTERLEUKIN 13; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 9; MEDI 528; UNCLASSIFIED DRUG;

ADD ON THERAPY; ASTHMA; BRONCHUS HYPERREACTIVITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG TARGETING; EOSINOPHILIA; HELPER CELL; HUMAN; MUCUS SECRETION; NONHUMAN; REVIEW; TREATMENT INDICATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ASTHMA; CLINICAL TRIALS AS TOPIC; HUMANS; INFLAMMATION; INTERLEUKIN-9;

MUS;

EID: 77950801090     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Magainin Pharmaceuticals and Genentech enter into collaborative research and option agreement in asthma. Magainin Pharmaceuticals Inc Press release 1999 January 07
2. Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. Temann UA, Geba GP, Rankin JA, Flavell RA J EXP MED 1998 188 7 1307-1320
3. Lung delivery of an interleukin-9 antibody treatment inhibits airway hyperreponsiveness (AHR), BAL eosinophila, mucin production, and serum IgE elevation to natural antigens in a murine model of asthma. McLane MP, Tepper J, Weiss C, Tomer Y, Taylor RE, Tumas D, Zhou Y, Haczhu A J ALLERGY CLIN IMMUNOL 2000 105 1 Pt 2 Abs 488
4. Magainin regains IL9 antibody development progrAM from Genentech - All licensed technology to be returned to Magainin. Magainin Pharmaceuticals Inc PRESS RELEASE 2000 December 19
5. Interleukin 9 promotes influx and local maturation of eosinophils. Louahed J, Zhou YH, Maloy WL, Rani PU, Weiss C, Tomer Y, Vink A, Renauld JC, Van Snick J, Nicolaides NC, Levitt RC et al BLOOD 2001 97 4 1035-1042
6. Interleukin-9 upregulates mucus expression in the airways. Louahed J, Toda M, Jen J, HAMid Q, Renauld JC, Levitt RC, Nicolaides NC AM J REPIR Cell MOL BIOL 2000 22 6 637-639
7. IL-9 induces chemokine expression in lung epithelial cells and baseline airway eosinophilia in transgenic mice. Dong Q, Louahed J, Vink A, Sullivan CD, Messler CJ, Zhou YH, Haczku A, Huaux F, Arras M, Holroyd KJ, Renauld JC et al EUR J IMMUNOL 1999 29 7 2130-2139
8. IL-9 pathway in asthma: New therapeutic targets for allergic inflammatory disorders. Levitt RC, McLane MP, MacDonald D, Ferrante V, Weiss C, Zhou T, Holroyd KJ, Nicolaides NC J ALLERGY CLIN IMMUNOL 1999 103 5 Pt 2 S485-S491
9. Interleukin-9 promotes allergen-induced eosinophilic inflammation and airway hyperresponsiveness in transgenic mice. Levitt RC, McLane MP, MacDonald D, Ferrante V, Weiss C, Zhou T, Holroyd KJ, Nicolaides NC AM J REPIR CELL MOL BIOL 1998 19 5 713-720
10. Targeting IL-9 during the inflammatory response. Holroyd K SMI CONF - ASTHMA: NEW DRUG TARG INNNOV THER 2001 March 28-29
11. MedImmune and Genaera enter agreement to develop products targeting REPIRatory disease. MedImmune Inc Press release 2001 April 20
12. Characterization of a calcium-activated chloride channel as a shared target of Th2 cytokine pathways and its potential involvement in asthma. Zhou Y, Dong Q, Louahed J, Dragwa C, Savio D, Huang M, Weiss C, Tomer Y, McLane MP, Nicolaides NC, Levitt RC AM J REPIR CELL MOL BIOL 2001 25 4 486-491
13. Lung delivery of an interleukin-9 antibody inhibits BAL interleukin-13 levels in a murine model of asthma. McLane M, Weiss C, Tomer Y, Kelly G, O'Brien PJ, Worthey A, Chen Q, Levitt RC J ALLERGY CLIN IMMUNOL 2002 109 1 Pt 2 Abs 5
14. Involvement of IL-9 in the bronchial phenotype of patients with nasal polyposis. Tsicopoulos A, Shimbara A, de Nadai P, Aldewachi O, LAMblin C, Lassalle P, Walls AF, Senechal S, Levitt RC, Darras J, Hamid Q et al J ALLERGY CLIN IMMUNOL 2004 113 3 462-469
15. Genaera announces achievement of CLINical development milestone by MedImmune, Inc. related to IL-9 antibody alliance. Genaera Corp PRESS REALASE 2004 August 18
16. MedImmune begins phase 1 Clinical trial for its anti-interleukin-9 monoclonal antibody. MedImmune Inc Press release 2004 August 18
17. NCT00394654: A study to evaluate the efficacy of MEDI-528 on late asthmatic response with atopic asthma. MedImmune Inc CLINICalTrIals.GOV 2007 May 8
18. MedImmune initiates phase 2a multi-dose study in patients with asthma. MedImmune Inc Press release 2007 August 01
19. Phase 2a multi-dose study initiated by MedImmune in patients with asthma to further expand anti-interleukin-9 program. Genaera Corp Press release 2007 August 01
20. MedImmune advances CLINical development of antibody targeting interleukin-9 in patients with asthma. MedImmune Inc PRESS RELEASE 2008 March 18
21. Genaera announces MedImmune initiation of phase 2a trial of antibody targeting interleukin-9 in patients with asthma. Genaera Corp PRESS RELEASE 2008 March 18
22. Targeting TNF-α: A novel therapeutic approach for asthma. Brightling C, Berry M, AMrani Y J ALLERGY CLIN IMMUNOL 2008 121 1 5-10
23. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O'Byrne PM N ENGl J MED 2009 360 10 985-993
24. Mepolizumab and exacerbations of refractory eosinophilic asthma. N ENGl J MED 2009 360 10 973-984
25. Two first-in-human, open-label, phase I dose-escalation safety trials of MEDI-528, a monoclonal antibody against interleukin-9, in healthy adult volunteers. White B, Leon F, White W, Robbie G CLIN THER 2009 31 4 728-740
26. A single dose of MEDI-528, a monoclonal antibody against interleukin-9, is well tolerated in mild and moderate asthmatics in the phase II trial MI-CP-138. O'Byrne P, Boulet LP, Gauvreau G, Leon F, Sari S, White B CHEST 2007 132 4 Suppl 478S
27. A randomized double-blind, placebo controlled multicenter study to evaluate the efficacy of a humanized interleukin-9 monoclonal antibody (MEDI-528) on the late asthmatic response in adults with atopic asthma. Gauvreau G, Boulet LP, Parker JM, Sari S, White B, MOLfno N, O'Byrne PM AM J REPIR CRIT Care Med 2009 179 A3639
28. Systemic administration of blocking IL-9 antibody inhibits airway hyperresponsiveness, eosinophilia and lung cytokine expression in ovalbumin model of asthma. McLane MP, Reed J, Weiss C ABS AM THORAC SOC 2003 99 Abs A356
29. Multiple subcutaneous doses of MEDI-528, a monoclonal antibody against interleukin-9 in mild and moderate asthmatics. LaForce C, Boulet L-P, Pearlman D, Fogarty C, Miller SD, Gauvreau G, Kaiser H, Lemiere C, Suri S, Parker JM, White B et al CHEST 2008 134 Abs s43002
30. IL-9 induces expression of granzymes and high-affinity IgE receptor in murine T helper clones. Louahed J, Kermouni A, Van Snick J, Renauld JC J IMMUNOL 1995 154 10 5061-5070
31. Th2 cytokines and asthma. Interleukin-9 as a therapeutic target for asthma. Zhou Y, Mclane M, Levitt RC RESPIR RES 2001 2 2 80-84
32. Pulmonary overexpression of IL-9 induces Th2 cytokine expression, leading to immune pathology. Temann UA, Ray P, Flavell RA J CLIN INVEST 2002 109 1 29-39
33. IL-13 mediates in vivo IL-9 activities on lung epithelial cells but not on hematopoietic cells. Steenwinckel V, Louahed J, Orabona C, Huaux F, Warnier G, McKenzie A, Lison D, Levitt R, Renauld JC J IMMUNOL 2007 178 5 3244-3251
34. Anti-TNF-α therapies in chronic obstructive pulmonary diseases. Antoniu SA, Mihaltan F, Ulmeanu R EXPERT OPIN INVEST DRUGS 2008 17 8 1203-1211
35. Global strategy for asthma management and prevention: GINA executive summary. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, Gibson P, Ohta K, O'Byrne P, Pedersen SE, Pizzichini E et al EUR RESPIR J 2008 31 143-178
36. Attitudes and actions of asthma patients on regular maintenance therapy: The INSPIRE study. Partridge MR, van der Molen T, Myrseth SE, Busse WW BMC PUlM MED 2006 6 13
37. Executive summary (non-confidential): Monoclonal antibody to interleukin-9 as therapy for moderate to severe persistent asthma. Genaera Corp COMPANY PRESENTATION 2009 November 09
38. Update to unit holders of the Genaera Liquidating Trust (the "Trust"). Genaera Corp COMPANY NEWSLETTER 2009 August 12
39. The demise of anti IL-5 for asthma, or not. O'Byrne PM AM J RESPIR CRIT CARE MED 2007 176 11 1059-1060
40. Cytokine antagonists for the treatment of asthma: Progress to date. Antoniu SA BIODRUGS 2009 23 4 241-251
41. Efficacy and safety of AMG 317, an IL-4Ra antagonist, in atopic asthmatic subjects: A randomized, double-blind, placebo-controlled study. Corren J, Busse W, Meltzer E, Mansfeld L, Bensch G, Chon Y, Dunn M, Weng H, Lin S J ALLERGY CLIN IMMUNOL 2009 123 3 732
42. Clinical safety of inhaled corticosteroids for asthma in children: An update of long-term trials. Pedersen S DRUG SAF 2006 29 7 599-612
43. IL-9 and its receptor in allergic and nonallergic lung disease: Increased expression in asthma. Shimbara A, Christodoulopoulos P, Soussi-Gounni A, Olivenstein R, Nakamura Y, Levitt RC, Nicolaides NC, Holroyd KJ, Tsicopoulos A, Lafitte JJ, Wallaert B J ALLERGY CLIN IMMUNOL 2000 105 (1 Pt 1) 108-115
44. A randomized, double-blind, placebo-controlled study of tumor necrosis factor-α blockade in severe persistent asthma. Wenzel SE, Barnes PJ, Bleecker ER, Bousquet J, Busse W, Dahlen SE, Holgate ST, Meyers DA, Rabe KF, Antczak A, Baker J et al AM J RESPIR CRIT CARE MED 2009 179 7 549-558